Loading
Thyroid Disorders and Treatments · Journal article
International Journal of Medical & Pharmaceutical Sciences · July 19, 2026
Raises a question worth testing. It does not answer one.
This is a review of an in vitro proof-of-concept study demonstrating that CRISPR-Cas9-mediated integration of a reconstructed ancestral uricase gene (AncUOX) into the AAVS1 safe harbor locus in HEK293 cells produces functional enzyme that degrades uric acid in a dose-responsive manner. The work is mechanistic and foundational but lacks in vivo validation, animal models, or any human data; it supports further investigation but does not establish therapeutic efficacy or safety.
In vitro cell engineering; single-arm, uncontrolled proof-of-concept study in cultured human cells (HEK293). HEK293 cells (human embryonic kidney-derived cell line). No patient population, no animal model, no in vivo human tissue.. Intervention: CRISPR-Cas9-mediated integration of ancestral uricase gene (AncUOX) into AAVS1 locus, with peroxisomal targeting signal (S-K-L).. Compared with: Non-transduced HEK293 control cells.. Not stated in the source text..
AncUOX protein expressed at expected molecular weight (~35 kDa) exclusively in RFP-positive (successfully transduced) cells. Immunofluorescent co-staining demonstrated robust colocalization of AncUOX with peroxisomes (PMP70 marker). Spectrophotometric uricase activity assays showed statistically significant reduction of exogenous uric acid relative to non-transduced controls at concentrations representing normouricemia (100 μM), moderate hyperuricemia (200–400 μM), and severe hyperuricemia (600 μM, ~10 mg/dL), p < 0.05; p < 0.01.
Cell culture only; no animal model, no human tissue, no in vivo efficacy or safety data.
This work does not yet support clinical application. The authors explicitly call for future translational studies using hepatocyte-specific delivery and organoid models before clinical advancement; practitioners should await in vivo and animal validation before considering this a viable therapeutic strategy.
This is a mechanistic proof-of-concept study in cultured cells demonstrating CRISPR-mediated gene integration and enzymatic activity, not a clinical trial or in vivo validation; it raises the question of whether this approach could work therapeutically rather than answering it.
As stated by the source record.
Quoted from the source exactly as published.
This work does not yet support clinical application. The authors explicitly call for future translational studies using hepatocyte-specific delivery and organoid models before clinical advancement; practitioners should await in vivo and animal validation before considering this a viable therapeutic strategy.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background and Rationale: Hyperuricemia—defined as serum uric acid levels exceeding 6 mg/dL in women and 7 mg/dL in men—is a globally prevalent metabolic disorder arising from the evolutionary silencing of the uricase gene in the primate lineage approximately 20 million years ago. This pseudogenization, caused by parallel nonsense mutations introducing premature stop codons, rendered humans and other great apes incapable of degrading uric acid beyond the monosodium urate stage. As a consequence, serum uric acid concentrations in humans (3–7 mg/dL) are substantially higher than in most other mammals (1–2 mg/dL) that retain a functional uricase enzyme. Clinically, elevated uric acid precipitates gout, urate nephropathy, hypertension, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD), representing a significant and growing burden on global health systems. Current pharmacological options, including xanthine oxidoreductase inhibitors (allopurinol, febuxostat) and recombinant uricase preparations (pegloticase/KRYSTEXXA), are limited by incomplete efficacy, high immunogenicity, and serious adverse events. While up to 40% of patients receiving pegloticase produce neutralizing antibodies, about 40% of patients treated with allopurinol do not reach therapeutic urate concentrations. These drawbacks have motivated the search for durable, genome-based solutions. Scope of This Review: This review examines CRISPR-Cas9 homology-directed repair (HDR) as a strategy to genomically integrate a reconstructed ancestral uricase gene (AncUOX) into the human AAVS1 safe harbor locus in HEK293 cells, focusing on the foundational study by Balico and Gaucher (2021). The AncUOX construct encodes a functionally active uricase retaining a peroxisomal targeting signal (S-K-L), ensuring organelle-specific compartmentalization. Two independent guide RNA sequences (gRNA1 and gRNA2) targeting the AAVS1 locus upstream of exon 2 were used by the original investigators in combination with a donor plasmid carrying 800-bp flanking homology arms, a splice acceptor sequence, RFP reporter, and AncUOX separated by T2A self-cleaving peptide sequences. A co-transfected Ad4E4orf6 protein facilitated NHEJ inhibition to promote HDR efficiency. Sanger sequencing, Western blot, immunofluorescence colocalization, and genomic PCR using junction-spanning primers all verified successful integration. Key Findings: AncUOX was precisely and sequence-verifiedly integrated into the AAVS1 locus under both gRNA1 and gRNA2 conditions. Western blot analysis confirmed AncUOX protein expression at the expected molecular weight (~35 kDa) exclusively in RFP-positive (successfully transduced) cells. Immunofluorescent co-staining with the peroxisomal membrane marker PMP70 demonstrated robust colocalization of AncUOX with peroxisomes. Importantly, spectrophotometric uricase activity assays showed that engineered cells effectively oxidized exogenous uric acid at concentrations representing normouricemia (100 μM), moderate hyperuricemia (200–400 μM), and severe hyperuricemia (600 μM, ~10 mg/dL), with statistically significant reduction relative to non-transduced controls (p < 0.05; p < 0.01). Conclusions: The work reviewed here represents the first successful genomic re-engineering of the primate uricase pseudogene in human cells, demonstrating that CRISPR-Cas9-mediated AncUOX integration confers measurable and sustained uricase enzymatic activity. The peroxisomal localization of AncUOX is anticipated to minimize immunogenicity while ensuring catalytic co-detoxification of hydrogen peroxide by-product via co-localized catalase. These results provide an evidence-based foundation for gene therapy strategies aimed at gout, chronic hyperuricemia, and related cardiometabolic disorders. This review argues that future translational studies using hepatocyte-specific delivery systems and organoid models are warranted to advance this approach toward clinical application.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.